Max Chat
Company Analysis Chengdu Kanghong Pharmaceutical Group Co., Ltd
1. Summary
Advantages
- The stock's return over the last year (12.15%) is higher than the sector average (-33.02%).
- The company's current efficiency (ROE=12.44%) is higher than the sector average (ROE=11.95%)
Disadvantages
- Price (16.8 Β₯) is higher than fair price (13.5 Β₯)
- Dividends (0.83%) are below the sector average (1.83%).
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Chengdu Kanghong Pharmaceutical Group Co., Ltd | Healthcare | Index | |
|---|---|---|---|
| 7 days | -4.9% | 0% | 4.7% |
| 90 days | -26.7% | -12% | 3.2% |
| 1 year | 12.1% | -33% | 37.3% |
002773 vs Sector: Chengdu Kanghong Pharmaceutical Group Co., Ltd has outperformed the "Healthcare" sector by 45.17% over the past year.
002773 vs Market: Chengdu Kanghong Pharmaceutical Group Co., Ltd has significantly underperformed the market by -25.15% over the past year.
Stable price: 002773 is not significantly more volatile than the rest of the market on "Shenzhen Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 002773 with weekly volatility of 0.2336% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (16.8 Β₯) is higher than the fair price (13.5 Β₯).
Price is higher than fair: The current price (16.8 Β₯) is 19.6% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (18.85) is lower than that of the sector as a whole (69.4).
P/E vs Market: The company's P/E (18.85) is lower than that of the market as a whole (63.57).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.32) is lower than that of the sector as a whole (3.96).
P/BV vs Market: The company's P/BV (2.32) is lower than that of the market as a whole (3.79).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (4.9) is lower than that of the sector as a whole (6.51).
P/S vs Market: The company's P/S indicator (4.9) is lower than that of the market as a whole (5.87).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (13.97) is higher than that of the sector as a whole (11.85).
EV/Ebitda vs Market: The company's EV/Ebitda (13.97) is lower than that of the market as a whole (25.54).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -85.13% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-85.13%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0%).
5.4. ROE
ROE vs Sector: The company's ROE (12.44%) is higher than that of the sector as a whole (11.95%).
ROE vs Market: The company's ROE (12.44%) is higher than that of the market as a whole (9.38%).
5.5. ROA
ROA vs Sector: The company's ROA (6.83%) is higher than that of the sector as a whole (5.4%).
ROA vs Market: The company's ROA (6.83%) is higher than that of the market as a whole (3.95%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0.83% is below the average for the sector '1.83%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0.83% has been steadily paid over the past 7 years, DSI=0.93.
Weak dividend growth: The company's dividend yield 0.83% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (10.42%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
